Pasithea Therapeutics Corp (NQ: KTTA )
4.551
-0.159
(-3.37%)
Streaming Delayed Price
Updated: 3:28 PM EDT, Aug 30, 2024
Add to My Watchlist
Press Releases about Pasithea Therapeutics Corp
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Exposures
COVID-19
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Exposures
COVID-19
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
March 08, 2022
Topics
Economy
Exposures
Economy
Exposures
COVID-19
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Exposures
COVID-19
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
November 23, 2021
Exposures
COVID-19
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
November 17, 2021
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Exposures
Product Safety
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
October 14, 2021
Exposures
COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.